FRANCINI, EDOARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.745
AS - Asia 3.018
EU - Europa 2.589
SA - Sud America 1.031
AF - Africa 67
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.480
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.673
RU - Federazione Russa 1.047
CN - Cina 909
BR - Brasile 808
SG - Singapore 709
PL - Polonia 526
VN - Vietnam 412
KR - Corea 389
HK - Hong Kong 348
IT - Italia 338
IE - Irlanda 268
AR - Argentina 114
SE - Svezia 84
ID - Indonesia 71
GB - Regno Unito 61
DE - Germania 57
DK - Danimarca 57
IN - India 49
EC - Ecuador 43
FI - Finlandia 38
BD - Bangladesh 32
CA - Canada 30
AU - Australia 28
MX - Messico 27
LU - Lussemburgo 25
IQ - Iraq 17
FR - Francia 16
BJ - Benin 15
CL - Cile 15
JO - Giordania 15
JP - Giappone 15
CO - Colombia 14
NL - Olanda 13
UA - Ucraina 12
ZA - Sudafrica 12
PE - Perù 11
ES - Italia 9
MA - Marocco 9
PY - Paraguay 8
TR - Turchia 8
CH - Svizzera 7
PK - Pakistan 7
UY - Uruguay 7
UZ - Uzbekistan 7
EG - Egitto 6
KE - Kenya 6
VE - Venezuela 6
AT - Austria 5
BO - Bolivia 5
TN - Tunisia 5
DZ - Algeria 4
KW - Kuwait 4
LT - Lituania 4
LV - Lettonia 4
AE - Emirati Arabi Uniti 3
BE - Belgio 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
HN - Honduras 3
IL - Israele 3
KZ - Kazakistan 3
RS - Serbia 3
SA - Arabia Saudita 3
AZ - Azerbaigian 2
HU - Ungheria 2
JM - Giamaica 2
KG - Kirghizistan 2
PH - Filippine 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
CR - Costa Rica 1
CY - Cipro 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
HT - Haiti 1
IR - Iran 1
LK - Sri Lanka 1
LY - Libia 1
MK - Macedonia 1
MN - Mongolia 1
MU - Mauritius 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
RO - Romania 1
SD - Sudan 1
SN - Senegal 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 11.480
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.968
Singapore 530
Warsaw 523
Seoul 388
Hefei 376
Fairfield 353
Hong Kong 309
Ashburn 308
Dublin 263
Woodbridge 184
Seattle 147
Ho Chi Minh City 141
Beijing 127
Cambridge 118
Wilmington 118
Dallas 116
Houston 100
Altamura 96
Lawrence 96
Moscow 82
Buffalo 81
Los Angeles 78
Hanoi 70
São Paulo 70
Copenhagen 57
Princeton 51
Florence 45
Kent 43
Dong Ket 40
Jakarta 40
San Diego 38
Chandler 36
The Dalles 36
Clifton 34
Boston 33
New York 33
Rio de Janeiro 33
Buenos Aires 28
Haiphong 28
Munich 28
Ann Arbor 27
Melbourne 26
Guangzhou 25
Medford 25
Rome 24
Curitiba 22
Mumbai 21
Chicago 19
Guayaquil 19
Redondo Beach 18
London 17
Shanghai 17
Siena 16
Cotonou 15
Milan 15
Quito 15
Tokyo 15
Da Nang 14
Norwalk 14
Salvador 14
Belo Horizonte 13
Brasília 13
Hải Dương 13
Lappeenranta 13
Bengaluru 12
Helsinki 12
Mexico City 12
Roodt-sur-Syre 12
Turku 12
Montreal 11
Thái Bình 11
Ninh Bình 10
Toronto 10
Biên Hòa 9
Falls Church 9
Campinas 8
Frankfurt am Main 8
Lima 8
Phoenix 8
Recife 8
West Jordan 8
Denver 7
Dhaka 7
Indaiatuba 7
Montevideo 7
Poplar 7
Porto Alegre 7
Salt Lake City 7
Tukwila 7
Yubileyny 7
Boardman 6
Boydton 6
Bắc Giang 6
Caxias do Sul 6
Chennai 6
Council Bluffs 6
Esch-sur-Alzette 6
Fortaleza 6
Hillsboro 6
Nairobi 6
Totale 7.966
Salva come PNG Salva come JPEG
Nome #
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience 274
An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer 185
Is there still a place for docetaxel rechallenge in prostate cancer? 184
Tumor fraction in cell-free DNA as a biomarker in prostate cancer 184
CD3+ tumor-infiltrating lymphocytes (TILs) as prognostic in patients (pts) with stage II colon cancer (CC) not treated with adjuvant chemotherapy (ADJ) 183
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study 177
Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer 176
Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer 176
Circulating free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC). 175
Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer 170
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience 166
Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer 164
Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer 156
A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient 155
Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study 148
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy 148
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer 147
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival 147
1204PGOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis 147
Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival 144
Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine 142
Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status 142
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate 141
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases 141
Hyperprogressive disease in advanced cancer patients treated with nivolumab: A case series study 140
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer 139
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study 136
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 136
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials 136
Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study 135
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry 134
Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database 133
Manuale di oncologia medica 132
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 131
Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC) 129
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) 129
The third line of treatment for metastatic prostate cancer patients: Option or strategy? 129
Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis 129
Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases 127
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study 126
Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma 125
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer 124
Prostate cancer: Developing novel approaches to castration-sensitive disease 124
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience 122
Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer 122
Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2 120
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer 117
Relevance of Gender In the Drug-utilization pattern of Non Small Cell Lung Cancer patients at University Hospital of Siena, Italy (UHS). 116
Association of concomitant bone resorption inhibitors with overall survival among patients with metastatic castration-resistant prostate cancer and bone metastases receiving abiraterone acetate with prednisone as first-line therapy. 116
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer 115
The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. 115
Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer 114
Targeted Therapies for Prostate Cancer 113
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer 112
Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer 110
Extramammary invasive Paget’s disease and apocrine angiomatous hamartoma: an unusual association 110
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer 109
Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience 108
Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength 107
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. 107
Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database 105
How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue 105
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 103
Efficacy of bone resorption inhibitors (BRI) plus abiraterone acetate plus prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry 103
Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer 103
PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials 103
Outcomes of Prechemotherapy (preCRx) Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after ADT + Docetaxel (D) or ADT Alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in a Multi-Institution Hospital-based Registry. 100
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 99
Specific clonal expansion at disease progression (PD) in solid cancers pinpointed by cell free DNA analysis. 98
Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies 98
No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide 97
Cell-Free DNA: Unveiling the Future of Cancer Diagnostics and Monitoring 97
Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) plus docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry 95
Genomic analysis of circulating tumor DNA identifies recurrent molecular features with clinical significance in advanced prostate cancer. 93
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study 91
Prior therapy and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based database 87
Clinical outcomes of sunitinib (Su) for patients (pts) with desmoid tumors (DT) 85
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review 84
Using Linked Administrative And Pathology Database To Describe Treatment Patterns Of Non-small-cell Lung Cancer Patients At The Azienda Ospedaliera Universitaria Senese 82
Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry 77
GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis 76
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer 75
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study 72
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 71
Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer 71
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy 70
Androgen Blockade and Salvage ­Radiation Therapy in Prostate Cancer: Cautious Optimism Amid Unanswered Questions 67
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study 63
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer 61
Oral Metronomic Chemo-Hormonal-Therapy of Metastatic Breast Cancer with Cyclophosphamide and Megestrol Acetate 58
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel 57
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study 56
FOLFOX-4 Stop and Go and Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer 55
Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab 54
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids 53
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors 50
Manuale di Oncologia Medica II edizione 50
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin 49
Weekly high‐dose calcitriol and docetaxel in patients with metastatic hormone‐refractory prostate cancer previously exposed to docetaxel 47
Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial) 45
Totale 11.504
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.156
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.156
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021494 0 0 0 0 0 59 54 46 113 102 71 49
2021/2022363 5 5 21 24 4 41 45 22 15 17 63 101
2022/2023631 77 203 37 34 4 116 95 8 43 0 8 6
2023/2024519 8 18 53 48 78 97 10 69 21 46 42 29
2024/20253.998 130 265 156 411 1.314 1.054 68 96 105 73 119 207
2025/20264.381 369 1.034 1.067 1.304 582 25 0 0 0 0 0 0
Totale 11.638